Personality traits and efficacy of anti-CGRP monoclonal antibodies in migraine prevention

Lovati, Carlo; Bernasconi, Gianna; Capogrosso, Chiara; Molteni, Laura; Giorgetti, Federica; Dell’Osso, Bernardo; Pantoni, Leonardo

doi:10.1007/s10072-022-06251-0

Cited by 4 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fourteen studies were excluded either because they were based on the same cohort as an included study or because they did not provide measures of the association of interest. We included 38 studies [ 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 ] in this review, which are summarized in Tables S1–S3 . The PRISMA flow diagram of the literature search process is displayed in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Associations were also seen between response failure and traits imbuing psychological vulnerability, such as personality disorders and the number of serious stressful events [ 45 ] ( Figure 9 ). Lovati et al [ 46 ] found non-responders (<30% reduction in MHD) scored higher on disinhibition, anhedonia, depressivity, and distractibility on the Personality Inventory for DSM-5 (PID-5) questionnaire than full-responders (>50% reduction in MHD) [ 46 ]. In Driessen et al, however, the response rate to fremanezumab was not significantly different in subgroups with major depressive disorder or generalized anxiety disorder [ 47 ].…”

Section: Resultsmentioning

confidence: 99%

“…Lee et al [ 63 ] assessed for depressive and anxiety symptoms using the Patient Health Questionnaire-9 (PHQ-9) [ 84 ] and the General Anxiety Disorder-7 (GAD-7) [ 85 ] and defined the presence of depression or anxiety using a cutoff value. Lovati et al [ 46 ] evaluated personality traits using the 220-item Personality Inventory for DSM-5 (PID-5) [ 86 ].…”

Section: Resultsmentioning

confidence: 99%

“…One possible explanation is that increasing severity of migraine conveys a higher risk of developing comorbid depression and anxiety disorder [ 45 ], and the associations that were observed are attributable to higher migraine disease burden at baseline. Interestingly, migraine patients with depressive symptoms had higher salivary CGRP levels independent of MHD [ 46 ], indicating that for comorbid depression, there seems to be a separate and added pathology beyond migraine severity that may contribute to treatment failure.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response

et al. 2023

View full text Add to dashboard Cite

Calcitonin gene-related peptide-targeted monoclonal antibodies (CGRP mAbs) are increasingly being used as preventive treatments for migraine. Their effectiveness and safety were established through numerous randomized placebo-controlled trials and real-world studies, yet a significant proportion of patients do not respond to this treatment, and currently, there is a lack of accepted predictors of response to guide expectations, as data from studies so far are lacking and inconsistent. We searched Embase and MEDLINE databases for studies reporting on predictors of response to CGRP and/or CGRP-receptor (CGRP-R) mAbs, defined as a 30% or 50% reduction in monthly headache or migraine days at varying durations of follow-up. Quantitative synthesis was performed where applicable. We found 38 real-world studies that investigated the association between various predictors and response rates. Based on these studies, good response to triptans and unilateral pain with or without unilateral autonomic symptoms are predictors of a good response to CGRP(-R) mAbs. Conversely, obesity, interictal allodynia, the presence of daily headaches, a higher number of non-successful previous prophylactic medications, and psychiatric comorbidities including depression are predictive of a poor response to CGRP(-R) mAbs. Future studies should confirm these results and help to generate more tailored treatment strategies in patients with migraine.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The nding that "Anhedonia" serves as an additional connecting bridge factor between somatic symptoms and depressive symptoms in hospitalized COVID-19 patients is consistent with previous research. "Anhedonia" is an essential symptom in the diagnosis of depression, and previous research has demonstrated a strong relationship between headache, pleasure de cit, and depression [45].…”

Section: Discussionmentioning

confidence: 99%

The intrinsic association between somatic symptoms and psychiatric symptoms among Chinese COVID-19 inpatients: A network analysis

Gao,

Ren,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background COVID-19 stands as the most impactful global public health event in the 21st century, affecting both physical and mental well-being. However, the connection between various somatic and psychiatric symptoms remains unclear. The purpose of the survey is to investigate the relationship between somatic and psychiatric symptoms. Methods The study involved 534 Chinese hospitalized COVID-19 patients. Self-evaluation of somatic symptoms in COVID-19 inpatients, patient health questionnaire-9, insomnia severity index, and the PTSD checklist-civilian version were used to quantify the levels of somatic, depression, insomnia, and post-traumatic stress disorder, respectively. The network analysis method by the R program was used to judge the bridge symptoms and the network differences by gender. Results In this survey, the depression-somatic symptom network revealed seven robust edges, including “Anosmia”-“Ageusia”, “Headache”-“Muscle pain”, “Stuffy nose”-“Cough”, “Cough”-“Anhedonia”, “Cough” - “Sleep”, “Cough”-“Fatigue”, and “Muscle pain”-“Fatigue”. The insomnia-somatic symptom network highlighted five robust edges, including “Sleep onset”-“Maintenance”, “Noticeability”-“Distress”, “Ageusia”-“Anosmia”, “Headache”-“Muscle pain”, and “Stuffy nose”-“Cough”. The PTSD-somatic symptom network featured five prominent edges, including “Ageusia”-“Anosmia”, “Headache”-“Muscle pain”, “Reminders avoidance”-“Thoughts avoidance”, “Hypervigilance”-“Startle”, and “Stuffy nose”-“Cough”. Simultaneously, “Cough”、“Anhedonia”、 “Noticeability”、“Libido loss” and “Sleep” as bridge factors linked somatic symptoms with psychiatric symptoms. No gender differences in the somatic- psychiatric symptoms network. Conclusions This study provides new perspectives for assessing and intervening in COVID-19 and other multisystem diseases.

show abstract

Different personality profiles in patients with cluster headache: a data-driven approach

et al. 2023

View full text Add to dashboard Cite

Personality traits and efficacy of anti-CGRP monoclonal antibodies in migraine prevention

Cited by 4 publications

References 3 publications

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response

A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response

The intrinsic association between somatic symptoms and psychiatric symptoms among Chinese COVID-19 inpatients: A network analysis

Different personality profiles in patients with cluster headache: a data-driven approach

Contact Info

Product

Resources

About